Published in final edited form as:

Tetrahedron Lett. 2011 August 17; 52(33): 4316–4319. doi:10.1016/j.tetlet.2011.06.042.

Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation

Joshua D. Thomas[†] and Terrence R. Burke Jr.*

Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

Abstract

Described herein is the design and synthesis of a discrete heterobifunctional PEG-based pyridyl disulfide/amine-containing linker that can be used in the Cu-free click preparation of bioconjugates. The title PEG-based pyridyl disulfide amine linker is a potentially useful reagent for preparing water-soluble disulfide-linked cargos. It may be particularly valuable in expanding the field of Cu-free click-based bioconjugations to include reductively labile antibody, polymer, or nanoparticle-based drug conjugates.

Keywords

bioconjugation; cleavable linker; Cu-free click reaction; pyridyl disulfide

In order to develop proteins that merge properties of antibodies with biologically active small molecules,^{1,2} we have recently begun modifying selenocysteine (Sec) antibody constructs (Fc-Sec) by introducing click-compatible functionality.³ This potentially allows the click-attachment of cytotoxic drugs, dyes or other cargo to the Fc portion. Clickable antibody conjugates may require biologically-cleavable linkers that allow release of cargo once delivery to the target has been achieved. However, traditional Huisgen azide-alkyne cycloaddition click reactions employing Cu-catalysis can be incompatible with sensitive protein functionality, and this is one reason why Cu-free click chemistries are gaining greater prevalence.⁴ Accordingly, versatile hetero-bifunctional linkers are needed that are both compatible with multiple types of Cu-free click reagents and incorporate biologically cleavable bonds.

One approach to introducing a point of bio-cleavage between cargo and carrier is the inclusion of a disulfide bond within the linking component.^{5–11} Disulfides are synthetically straight-forward to manipulate, and although they are stable under a variety of conditions, they can be efficiently cleaved by reducing agents. Disulfides exhibit good stability in the circulation due to the low reducing potential of blood. In contrast, intracellular concentrations of reducing agents, such as glutathione, are typically 1000-fold greater than

*Corresponding author. Tel. +1 340 846 5906; fax: +1 340 846 6033, tburke@helix.nih.gov.

[†]Currently with Mersana Therapeutics, Cambridge, MA 02139

Supplementary data

Supplementary data (experimental procedures and spectroscopic data for all new compounds) can be found in the online version at doi:

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in the blood,¹² with the reductive potential within cancer cells being even higher.^{13,14} For these reasons, disulfide-containing constructs can afford effective vehicles for delivery to the cellular targets, and subsequent reductive release of cargo.

Currently available Cu-free click reagents commonly exhibit considerable hydrophobic character.⁴ Since cytotoxic drugs also tend to be highly hydrophobic, overcoming poor water solubility can be an important consideration in designing a Cu-free clickable linker for use in Fc-Sec conjugates. The commercially available 2-(pyridyldithio)-ethylamine (PDA)¹⁵ is a reagent used for the introduction of short disulfide-containing linkages. Unfortunately, conjugates based on a PDA linker could potentially exhibit unacceptably low solubility in aqueous media. Alternatively, polyethylene glycol (PEG) is a highly water-soluble construct that is used in a range of hetero-bifunctional linkers. However, none of the commercially available PEG-based reagents contain the combination of an activated disulfide (e.g., pyridyl disulfide) together with amine functionality that we desired in our current work. Additionally, previously reported PEG-based pyridyl disulfide/amine-containing linkers have been prepared by polymerization reactions that yield heterogeneous reactions products.¹⁶ Herein we describe the design and synthesis of a discrete heterobifunctional PEG-based pyridyl disulfide/amine-containing linker (**1**) that can be used in the Cu-free click preparation of bioconjugates either by initial coupling of a bioactive molecule through disulfide formation (Route A, Scheme 1) or by initial introduction of the click reagent by amide bond formation (Route B, Scheme 1). (Insert Scheme 1)

Discrete, highly pure PEG linkers that range in length from 8¹⁷ to 48¹⁸ ethylene glycol units can be prepared from tetraethylene glycol precursors. Our route to **1** began by the monobenzoylation of tetraethylene glycol (Scheme 2). Subsequent tosylation of **2** and chain elongation with excess tetraethylene glycol gave **3** in modest yield. Conversion of the primary alcohol to the mesylate and reaction with potassium phthalimide provided the protected amine **4**, which was debenzylated, brominated, and then reacted with triphenylmethanethiol to yield the doubly protected amino thiol **6**. An activated disulfide was introduced in two steps by removing the S-trityl group in **6** and then reacting the free thiol with pyridylsulfenyl chloride to afford **7** (Scheme 2).

Given the tendency of unsymmetrical disulfides to undergo base and temperature-induced degradation,¹⁹ cleavage of the phthalimide group in **7** to yield the free amine **1** could be problematic with commonly used conditions (hydrazine in refluxing ethanol).²⁰ However, the stability of a 2-pyridyldithio-based amino protecting group under piperidine-mediated Fmoc-deblock conditions,²¹ indicated that the 2-pyridyl group in **7** could potentially stabilize the disulfide bond during treatment with hydrazine. None-the-less, our initial efforts to remove the phthalimide group in **7** using standard hydrazine conditions gave significant disulfide disproportionation (as determined by ESI-MS) that resulted in a relatively low yield of the desired product **1** (48%). However, performing the reaction at ambient temperature decreased side reactions and resulted in an improved yield (71%). To assure stability during storage, the free amine group in **1** was protected with the acid-labile 4-methyltrityl (Mtt) group (compound **8** Scheme 2). The mild conditions required to remove the Mtt group make it compatible with a broad range of disulfide-linked cargo.

To demonstrate the utility of **8**, a cytotoxic derivative of cemadotin²² was appended to one end of the linker via a disulfide bond, and a tetrazine construct (**9**)²³ was introduced to the other end. The tetrazine serves as a diene that undergoes irreversible Cu-free click reactions through very efficient [2+4] inverse-electron-demand Diels-Alder cycloadditions with strained alkenes.⁴ In order to avoid potential side reactions with free thiols,²⁴ **9** was introduced following disulfide exchange with the thiol-containing bioactive cemadotin analog **10**²⁵ (Scheme 3). Cemadotin derivatives represent attractive drug cargos for

validating the synthetic strategy outlined in Scheme 3, because they contain *N*-alkylated tripeptide sequences that are prone to acid-catalyzed degradation.²⁶ Disulfide exchange between **8** and **10** and evaporation of solvent gave a crude reaction mixture, which was in modest subjected to Mtt removal (1% TFA in CH₂Cl₂) to provide **11** yield (Scheme 3). Importantly, no degradation of **10** was observed during under these conditions. Coupling of **11** to **9** (HOAt, diisopropylcarbodiimide and diisopropylethylamine in DMF) gave the fully elaborated construct **12**.

Linker **8** was also used to prepare clickable biotin-containing derivatives **15** and **16** (Scheme 4). Biotin-(STrt)cystamine **13** was converted in three steps to disulfide-containing amine **14** (Scheme 4). HATU-mediated coupling with **9** yielded biotin-containing tetrazine **15**, while reaction of **14** with OSu-activated azido acetic acid yielded the corresponding azide **16**. Since classical click reactions³ require a reducing agent in order to maintain copper in the +1 oxidation state, disulfides such as **16** are potentially better suited for Cu-free reactions that utilize highly strained cyclooctynes.⁴

In conclusion, we have shown that the PEG-based pyridyl disulfide amine linker **1** is a useful reagent for preparing water-soluble disulfide-linked cargos. It may be particularly valuable in expanding the field of Cu-free click-based bioconjugations, where applications have traditionally been related to imaging agents. Reagents such as **1** may extend the use of Cu-free click reagents to include reductively labile antibody, polymer, or nanoparticle-based drug conjugates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by the Intramural Research Program of the NIH, Center for Cancer Research, NCI-Frederick and the National Cancer Institute, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References and notes

1. Hofer T, Thomas JD, Burke TR Jr, Rader C. *Proc Nat Acad Sci U S A*. 2008; 105:12451.
2. Hofer T, Skeffington LR, Chapman CM, Rader C. *Biochemistry*. 2009; 48:12047. [PubMed: 19894757]
3. Kolb HC, Finn MG, Sharpless KB. *Angewandte Chem Int Ed Engl*. 2001; 40:2004.
4. Jewett JC, Bertozzi CR. *Chem Soc Rev*. 2010; 39:1272. [PubMed: 20349533]
5. Saito G, Swanson JA, Lee KD. *Adv Drug Deliv Rev*. 2003; 55:199. [PubMed: 12564977]
6. Ojima I. *Acc Chem Res*. 2008; 41:108. [PubMed: 17663526]
7. Carter PJ, Senter PD. *Cancer J*. 2008; 14:154. [PubMed: 18536555]
8. Low PS, Kularatne SA. *Curr Opin Chem Biol*. 2009; 13:256. [PubMed: 19419901]
9. van der Vlies AJ, O'Neil CP, Hasegawa U, Hammond N, Hubbell JA. *Bioconjug Chem*. 2010; 21:653. [PubMed: 20369815]
10. Leamon CP, Low PS. *J Biol Chem*. 1992; 267:24966. [PubMed: 1460001]
11. Zhu L, Mahato RI. *Bioconjug Chem*. 2010; 21:2119. [PubMed: 20964335]
12. Meister A, Anderson ME. *Annu Rev Biochem*. 1983; 52:711. [PubMed: 6137189]
13. Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Beckett GJ, Hayes JD, Wolf CR. *Carcinogenesis*. 1990; 11:451. [PubMed: 2311189]
14. Balendiran GK, Dabur R, Fraser D. *Cell Biochem Funct*. 2004; 22:343. [PubMed: 15386533]

15. Zugates GT, Anderson DG, Little SR, Lawhorn IEB, Langer R. J Am Chem Soc. 2006; 128:12726. [PubMed: 17002366]
16. Breitenkamp, K.; Sill, Kevin, N.; Skaff, H. Patent Cooperation Treaty (PCT). Organization, publication WO. 2007/127473 A2. November 8. 2007
17. Pilkington-Miksa MA, Sarkar S, Writer MJ, Barker SE, Shamlou PA, Hart SL, Hailes HC, Tabor AB. Eur J Org Chem. 2008:2900.
18. French AC, Thompson AL, Davis BG. Angew Chem Int Ed Engl. 2009; 48:1248. [PubMed: 19142918]
19. Field L, Parsons TF, Pearson DE. J Org Chem. 1966; 31:3550.
20. Wuts, PGM.; Greene, TW. Greene's Protective Groups in Organic Synthesis. 4. Wiley-Interscience; Hoboken, NJ 07030-5774: 2007.
21. Lapeyre M, Leprince JMM, Oulyadi H, Renard PY, Romieu A, Turcatti G, Vaudry H. Chem Eur J. 2006; 12:3655.
22. de Arruda M, Cocchiaro CA, Nelson CM, Grinnell CM, Janssen B, Haupt A, Barlozzari T. Cancer Res. 1995; 55:3085–3092. [PubMed: 7606731]
23. Pipkorn R, Waldeck W, Diding B, Koch M, Mueller G, Wiessler M, Braun K. J Peptide Sci. 2009; 15:235. [PubMed: 19177421]
24. Blackman ML, Royzen M, Fox JM. J Am Chem Soc. 2008; 130:13518. [PubMed: 18798613]
25. Thomas Joshua D, Rader C, Burke TR Jr. Unpublished results. 2011
26. Anteunis MJO, van der Auwera C. Int J Peptide Protein Res. 1988; 31:301.

Scheme 1.

Structure of PEG pyridyl disulfide amine linker **1** and its use in the construction of bioconjugates by two routes.

Scheme 2.

Reagents and Conditions: a) BnBr , NaH , THF (74%); b) TsCl , Et_3N , DMAP , CH_2Cl_2 (93%); c) (i) MsCl , Et_3N , CH_2Cl_2 ; (ii) potassium phthalimide, DMF (60% over two steps); d) (i) $\text{Pd} \cdot \text{C}$, H_2 , EtOH (78%); (ii) Ph_3P , CBr_4 , CH_2Cl_2 (70%); e) TrtSH , NaH , DMF (88%); f) (i) $\text{TFA}/\text{CH}_2\text{Cl}_2/(i\text{-Pr})_3\text{SH}$; (ii) 2-mercaptopyridine, SOCl_2 , CH_2Cl_2 , (51% over two steps); g) NH_2NH_2 , (71%); h) MttCl , DIEA , DMF (40%).

Scheme 3.

Reagents and Conditions: a) (i) **8**, MeOH (74%); (ii) TFA/CH₂Cl₂/*i*-Pr₃SH (39% for two steps); b) HOAt, DIC, DIEA, DMF (31%).

Scheme 4.

Reagents and Conditions: a) (i) TFA/CH₂Cl₂/(*i*-Pr)₃SH; (ii) **8**, MeOH (74%); (iii) TFA/CH₂Cl₂/(*i*-Pr)₃SH; b) **9**, HOAt, DIEA, DMSO (15% overall from **13**); c) 1-[(azidoacetyl)oxy]pyrrolidine-2,5-dione, MeCN/H₂O (6% overall from **13**).